Select region:

Clinical trials located in

Frankfurt

Frankfurt city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Frankfurt, nestled along the Main River, stands as Germany’s financial powerhouse, hosting the European Central Bank. This city uniquely blends modern skyscrapers with historic sites like Römerberg. Frankfurt birthed the famed writer Johann Wolfgang von Goethe, whose house is now a museum. It’s also known for the Frankfurt Book Fair, the world’s largest trade fair for books. The city’s culinary scene is renowned for its “Frankfurter” sausages. Frankfurt’s green spaces and the Main Tower’s panoramic views highlight its diverse character.

  • CT-EU-00112464

    Testing setmelanotide for weight loss in genetic obesity

    This study is a research project looking into the effectiveness of a medication called setmelanotide for people who are dealing with obesity due to specific genetic variations. This medication is given under the skin. The study is designed to see if setmelanotide can help people lose weight compared to a placebo, which don’t contain any active medication.

    The study focuses on individuals who have one of several gene variants in the Melanocortin-4 Receptor pathway. These variants include changes in the POMC or PCSK1 genes, the LEPR gene, the SRC1 gene, or the SH2B1 gene. Depending on which gene variant a participant has, they will be placed into one of four sub-studies.

    The main goal of this clinical trial is to measure how much weight participants lose while taking setmelanotide over a period of 52 weeks. This will be compared to the weight loss of participants who receive the placebo. The study is carefully controlled and blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo until the study is completed.

    This trial is an important step in understanding how setmelanotide can help people with obesity linked to specific genetic factors, offering hope for a targeted treatment option.

    FranceGermanyGreeceNetherlandsSpainUnited Kingdom
  • Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    FranceGermany
  • CT-EU-00053821

    Testing the safety and efficacy of Rapcabtagene autoleucel in combination with ibrutinib for the treatment of various leukemia

    This study is looking at a new drug called rapcabtagene autoleucel in people with different types of blood cancer. The treatment is divided into two phases. In phase I, the study is testing the safety and efficacy of the new treatment in three different patient groups. The first group is adults with CLL/SLL, a type of blood cancer that has not shown a good response to the drug ibrutinib. The second group is adults with DLBCL, another type of blood cancer, who have failed at least two other treatments and who are unable or unwilling to undergo a stem cell transplant. The third group is adults with ALL, another type of blood cancer, who have not responded to other treatments. Phase II extends Phase I, focusing on the two main groups. The aim of this part is to obtain additional information on the efficacy of the new treatment. The aim of both phases is to determine the best dose of rapcabtagene autoleucel, to see how safe it is and how well it works against these tumors. After the treatment part of the study is completed, patients will be followed up for at least two years to monitor their health status and the long-term effects of the treatment.

  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    AustriaGermanySpainUnited Kingdom
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    BelgiumFranceGermanyGreeceHungaryItalyNetherlandsSpainUnited Kingdom
  • Study of the effectiveness of a new drug in the treatment of heart failure and pulmonary hypertension

    This clinical trial explores the potential benefits of AZD3427 for individuals with heart failure (HF) and pulmonary hypertension (PH) Group 2, a condition characterized by increased blood pressure in the lungs due to heart disease. Around 220 participants will be randomly assigned to receive either AZD3427 or a placebo through subcutaneous injections every two weeks for 24 weeks. The trial aims to assess the impact of AZD3427 on reducing pulmonary vascular resistance (PVR) and improving various heart and lung health indicators. Participants will undergo multiple study visits, with the total duration of the study being approximately 32 to 37 weeks.

    AustriaCzechiaDenmarkGermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    BelgiumDenmarkGermanyItalyNorwayPolandSpainUnited Kingdom
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    BelgiumFinlandFranceGermanyGreeceItalyNetherlandsNorwayPortugalSpainSwedenUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Long-term study on donidalorsen in hereditary angioedema

    This is a research assessing the long-term safety and effectiveness of donidalorsen in the prophylactic treatment of hereditary angioedema (HAE-1 and HAE-2). The study includes two groups of participants: 1) individuals transitioning from another study with donidalorsen, and 2) new participants not transitioning from another donidalorsen study, who were previously on prophylactic therapy with lanadelumab, berotralstat, or a C1-esterase inhibitor (C1-INH). The duration of participation in the study is 70 or 76 weeks.

    BelgiumBulgariaFranceGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Study on a new combination therapy for advanced liver cancer

    This study is about trying out a new treatment plan for people with untreated advanced/metastatic hepatocellular carcinoma (HCC). The treatment involves using a combination of three drugs (nivolumab, relatlimab, bevacizumab) compared to a combination of two (nivolumab and bevacizumab). The purpose is to see if adding the third drug can make the treatment more effective, and also to confirm if it’s safe.

    FranceGermanyItalyPolandSpain
  • Study of nivolumab + relatlimab for new advanced melanoma cases

    The study explores the effects of combining Nivolumab and Relatlimab, given subcutaneously, in treating melanoma that hasn’t been treated before and can’t be surgically removed. The focus is on the medication levels in the blood and comparing the treatment’s impact on the disease with standard methods​​.

    AustriaBelgiumCzechiaFinlandFranceGermanyItalyNorwayPolandSpainSwedenUnited Kingdom
  • Exploring the effectiveness and safety of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia treatment

    This study aims to investigate the efficacy of a new treatment called tisagenlecleucel in helping children and young adults combat B-cell Acute Lymphoblastic Leukemia (B-ALL), a high-risk form of blood cancer. The research is conducted across multiple hospitals and involves several stages, including eligibility assessments, treatment preparation, treatment administration, regular check-ups to monitor progress, and long-term follow-up. After receiving tisagenlecleucel, patients will have more frequent hospital visits in the initial month, followed by regular visits every few months for the first two years, and then annually until the study concludes, approximately eight years after the first patient undergoes treatment.

    BelgiumDenmarkFinlandGermanyItalyNetherlandsNorwaySpainSwedenUnited Kingdom
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Study on brigimadlin for advanced cancer patients

    This clinical trial called “Brightline-2” is testing a new drug called brigimadlin (BI 907828). The drug is currently being studied to see if it can help patients with advanced cancer of the pancreas, bile ducts, lungs or bladder. Especially when other treatments are no longer effective or simply do not exist for them. Patients who choose to participate will take BI 907828 tablet every 3 weeks. Part of the test will include regular visits to the hospital or clinic to check how the tumor is responding to treatment and whether the spread of the cancer to other parts of the body has been controlled. There will also be regular health checks to check for any side effects of the medicine.

    AustriaBelgiumFranceGermanySpainUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Studying rimegepant’s effectiveness on Migraine

    This study is testing a new treatment, rimegepant, for adults with migraines who cannot take traditional migraine medications, such as triptans, possibly due to reasons like having a heart condition. The research aims to evaluate the effectiveness and tolerability of rimegepant over a 12-week period. Participants will be asked to rate their headache pain on a scale ranging from 0 (no pain) to 3 (severe pain) as one of the methods to assess the treatment’s impact.

    AustriaBelgiumDenmarkFinlandFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Study of new potential drug in breast cancer and solid tumors

    This study investigates LOXO-783 as a potential treatment for advanced breast cancer and various solid tumors with a specific genetic mutation (PIK3CA gene). The research explores the safety, side effects, and effectiveness of LOXO-783 when administered alone or in combination with other anticancer therapies. Participation in the study may last up to 36 months, with the potential for an extended duration if the disease does not progress. The aim is to gain valuable insights into the treatment of these cancers and improve our understanding of LOXO-783 in different therapeutic combinations.

    BelgiumFranceGermanySpainUnited Kingdom

See more clinical trials in other cities in Germany:

.